NDOIinactive

Endo LP

Healthcare·Oncology·Commercial
OncologyMetabolicDermatologyEndocrinologyReproductive

Endo LP (NDOI): 9 pipeline candidates · ~13 mo cash runway · 6 clinical trials. Updated within the last hour.

8.4/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway3.5

12.6 months

Financial Health10.0

0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

9 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Endo LPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$461.6M

Quarterly Burn

$180.7M

Runway

12.6 mo

Revenue

$392.8M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2027
Today~14 mo out
Catalyst within runway

Pipeline (9 candidates)

DrugPhase
aveedApproved
aveedApproved
collagenase clostridium histolyticumPhase 2
en3835Phase 2
percutaneous surgical set with 5mm or 10mm attachments—
percutaneous surgical set with 5mm or 10mm attachments—
supprelin laApproved
supprelin laApproved
xiaflexPhase 2
6 clinical trials·2 FDA decisions·CEO: Scott Hirsch

Frequently asked questions

How many drug candidates are in Endo LP's pipeline?

Endo LP (NDOI) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Endo LP's lead drug candidate?

Endo LP's most advanced tracked candidate is aveed (Approved) for 1 INDICATIONS AND USAGE AVEED is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (.

What is Endo LP's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Endo LP has approximately 12.6 months of cash runway.

Who is the CEO of Endo LP?

Scott Hirsch is the chief executive officer of Endo LP (NDOI).

Get the full picture on Endo LP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar